Helus Pharma Taps Former Intra-Cellular President Michael Halstead as CEO Ahead of Pivotal Phase 3 Readout
HELP has more than doubled off its 52-week low of $3.76 on light trading volume (0.2× avg).
Summary
Helus Pharma has appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO. Halstead's track record includes steering CAPLYTA through approvals and a $14.6B acquisition. The move comes as the company approaches pivotal Phase 3 data for its lead asset HLP003 in Q4 2026.
Key Events · Executive and Board Changes · HELP
-
New CEO Appointed
Michael Halstead, former President of Intra-Cellular Therapies, has been named CEO of Helus Pharma, effective immediately. He led Intra-Cellular's transformation and its $14.6B sale to Johnson & Johnson.
-
Strategic Timing
The appointment comes as Helus prepares for topline data from the APPROACH Phase 3 study of HLP003 in major depressive disorder, expected in Q4 2026.
-
Clinical Program Update
Enrollment is complete in APPROACH, while enrollment continues in EMBRACE (the second pivotal study) and EXTEND (the long-term extension).
-
Commercialization Experience
Halstead was instrumental in the development, launch, and commercialization of CAPLYTA across multiple indications, experience directly relevant to Helus's late-stage pipeline.
Analysis · HELP · Life Sciences
Helus Pharma (Cybin Inc.) has named Michael Halstead as CEO, effective immediately. Halstead previously served as President of Intra-Cellular Therapies, where he was instrumental in building the company from an early-stage venture to a $14.6 billion acquisition by Johnson & Johnson. His deep expertise in late-stage development and commercialization arrives at a critical juncture: Helus expects topline data from the APPROACH Phase 3 trial of HLP003 in major depressive disorder in Q4 2026. The appointment underscores a strategic pivot toward execution and market readiness, though it does not alter the fundamental binary risk tied to the upcoming data readout.
At the time of this filing, HELP was trading at $7.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $9.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.